# Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

> **NCT00305487** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 660 (—)

## Conditions studied

- Hay Fever
- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Ciclesonide nasal spray

## Key facts

- **NCT ID:** NCT00305487
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 660 (—)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305487, "Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00305487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*